<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1037">
  <stage>Registered</stage>
  <submitdate>17/01/2006</submitdate>
  <approvaldate>17/01/2006</approvaldate>
  <nctid>NCT00279435</nctid>
  <trial_identification>
    <studytitle>Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study</studytitle>
    <scientifictitle>A Randomized, Double-blind, Multicenter Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>291-417</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - visilizumab

Placebo Comparator: placebo - 

Experimental: visilizumab - 


Treatment: drugs: visilizumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>-  Males and females, 18 years of age or older.

          -  Only 1 prior treatment course with visilizumab (or placebo in a blinded visilizumab
             study).

          -  Response (as defined in parent protocol) of intravenous steroid-refractory ulcerative
             colitis (IVSR-UC) disease to visilizumab or placebo.

          -  Symptomatic worsening (ie, an increase of =3 points in MTWSI score) from the subject's
             best response on the parent study, an MTWSI score of =9, sustained for at least 2
             assessments performed at least 1 week apart, and a confirmatory MTWSI =8 within 1 day
             prior to randomization.

          -  CD4^+ T-cell count = 200 cells/mcL at screening for this protocol, or = 80% of the
             subject's screening baseline count prior to enrollment on the parent study.

          -  Mayo assessment (including flexible sigmoidoscopy) performed by a trained, blinded
             evaluating physician within 2 weeks prior to randomization.

          -  Adequate contraception from the day of consent through 3 months after the last dose of
             study drug.

          -  Negative serum pregnancy test.

          -  Negative Clostridium difficile test.

          -  Signed and dated informed consent, and Health Insurance Portability and Accountability
             Act (HIPAA) if applicable.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  UC requiring immediate surgical, endoscopic, or radiologic interventions.

          -  White blood cell count less than 2.5 x 10^3/mcL; platelet count less than 150 x
             10^3/mcL; or hemoglobin less than 8 g/dL.

          -  Active, medically significant infections, particularly those of viral etiology, eg,
             known cytomegalovirus (CMV) colitis. This includes any incidence of opportunistic
             infections within the past 12 months.

          -  Live vaccination within 6 weeks prior to randomization.

          -  Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary,
             vascular, gastrointestinal, endocrine, or laboratory abnormality, history of
             myocardial infarction, coronary artery disease, congestive heart failure, or
             arrhythmias within 6 months prior to consent.

          -  History of lymphoproliferative disorder (LPD) or malignancy other than nonmelanoma
             skin cancer or carcinoma in situ of the cervix that has been adequately treated within
             the past five years.

          -  Seropositive for infection with human immunodeficiency virus (HIV-1), hepatitis B
             virus (HBV) surface antigen, or hepatitis C virus (HCV).

          -  Pregnancy or nursing.

          -  Treatment with any other UC salvage drugs (including but not limited to infliximab or
             another anti-TNF-a drug, cyclosporine, tacrolimus [FK506], adalimumab, thalidomide, or
             another experimental agent), or therapies (surgery, pheresis, affinity columns) since
             the first course of treatment with study drug in the parent visilizumab study.

          -  Treatment with any other investigational drug or therapy within 60 days prior to
             randomization.

          -  Nontherapeutic levels of chronic antiseizure medications in subjects with a history of
             seizures.

          -  Any condition that, in the investigator's opinion, makes the subject unsuitable for
             study participation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Box Hill</hospital>
    <hospital> - Fremantle</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Liverpool</hospital>
    <postcode>3128 - Box Hill</postcode>
    <postcode>6160 - Fremantle</postcode>
    <postcode>QLD 4029 - Herston</postcode>
    <postcode>2170 - Liverpool</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ghent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Osijek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Csabai kapu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szekszárd</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Vac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Vasvári Pál</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Tromso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Facet Biotech</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>PDL BioPharma, Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and
      immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior
      visilizumab study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00279435</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>